NCT00016367View on ClinicalTrials.gov

Cisplatin and Gemcitabine Plus Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

May 13, 1999

Primary Completion Date

December 14, 2004

Study Completion Date

December 14, 2004

Conditions
Lung Cancer
Interventions
BIOLOGICAL

Trastuzumab

"Regimen A: Trastuzumab IV over 90 minutes on days 2 and 8.~Regimen B: Trastuzumab IV over 30-90 minutes on days 1, 8 and 15."

DRUG

Cisplatin

"Regimen A: Cisplatin IV over 2 hours on day 1 following gemcitabine.~Regimen B: Cisplatin IV over 2 hours on day 1."

DRUG

Gemcitabine Hydrochloride

"Regimen A: Gemcitabine IV over 30 minutes on day 1. Gemcitabine IV over 30 minutes on day 8 following Trastuzumab.~Regimen B: Gemcitabine IV over 30 minutes on day 1. Gemcitabine IV over 30 minutes on day 8 following Trastuzumab."

Trial Locations (1)

77030-4009

University of Texas - MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER